Redacci. Pen sula 360 Press [P360P].
Biotechnology company Moderna announced Monday that it plans to apply for emergency use authorization from the U.S. Food and Drug Administration (FDA) and conditional approval from the European Medicines Agency (EMA) for its COVID-19 vaccine.
The above is because the main efficacy analysis of the phase 3 study of ARNm-1273 carried out in 196 cases confirms the high efficacy observed in the first interim analysis, since the data indicate an efficacy of 94.1 percent.
The American company reported in a statement that the safety data continues